Use of positron emission tomography to target prostate cancer gene therapy by oncolytic herpes simplex virus

Michael Mullerad, David P. Eisenberg, Timothy J. Akhurst, Prasad S. Adusumilli, Christopher C. Riedl, Amit Bhargava, Mithat Gonen, Ronald Finn, Peter T. Scardino, Yuman Fong

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Herpes simplex virus (HSV) oncolytic gene therapy is a promising treatment modality against cancer. We have demonstrated that androgen-induced cellular changes enhance oncolytic viral replication and improve efficacy in the treatment of androgen-dependent prostate cancer cell line. Imaging of changes in 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) uptake by positron emission tomography (PET) is a sensitive method of detecting altered cellular metabolism involved in cancer therapy. We therefore hypothesized that FDG-PET can predict tumor response to oncolytic HSV therapy. In this study, androgen increased cell kill (74%) in vitro and enhanced viral yield (2.4-fold) in vivo following HSV therapy. This enhanced efficacy was predicted by high FDG accumulation in intact animals compared to low FDG uptake following orchiectomy (p = 0.002). This proof-of-concept study provides the mechanistic basis for selecting patients for targeted oncolytic viral therapy by means of a noninvasive molecular imaging method in the treatment of prostate cancer.

Original languageEnglish (US)
Pages (from-to)30-35
Number of pages6
JournalMolecular Imaging and Biology
Volume8
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Oncolytic Viruses
Neoplasm Genes
Simplexvirus
Genetic Therapy
Positron-Emission Tomography
Prostatic Neoplasms
Androgens
Oncolytic Virotherapy
Therapeutics
Neoplasms
Molecular Imaging
Orchiectomy
Glucose
Cell Line

Keywords

  • Fluorodeoxyglucose
  • Herpes virus
  • Hormonal therapy
  • Prediction

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Radiology Nuclear Medicine and imaging

Cite this

Mullerad, M., Eisenberg, D. P., Akhurst, T. J., Adusumilli, P. S., Riedl, C. C., Bhargava, A., ... Fong, Y. (2006). Use of positron emission tomography to target prostate cancer gene therapy by oncolytic herpes simplex virus. Molecular Imaging and Biology, 8(1), 30-35. https://doi.org/10.1007/s11307-005-0028-x

Use of positron emission tomography to target prostate cancer gene therapy by oncolytic herpes simplex virus. / Mullerad, Michael; Eisenberg, David P.; Akhurst, Timothy J.; Adusumilli, Prasad S.; Riedl, Christopher C.; Bhargava, Amit; Gonen, Mithat; Finn, Ronald; Scardino, Peter T.; Fong, Yuman.

In: Molecular Imaging and Biology, Vol. 8, No. 1, 01.2006, p. 30-35.

Research output: Contribution to journalArticle

Mullerad, M, Eisenberg, DP, Akhurst, TJ, Adusumilli, PS, Riedl, CC, Bhargava, A, Gonen, M, Finn, R, Scardino, PT & Fong, Y 2006, 'Use of positron emission tomography to target prostate cancer gene therapy by oncolytic herpes simplex virus', Molecular Imaging and Biology, vol. 8, no. 1, pp. 30-35. https://doi.org/10.1007/s11307-005-0028-x
Mullerad, Michael ; Eisenberg, David P. ; Akhurst, Timothy J. ; Adusumilli, Prasad S. ; Riedl, Christopher C. ; Bhargava, Amit ; Gonen, Mithat ; Finn, Ronald ; Scardino, Peter T. ; Fong, Yuman. / Use of positron emission tomography to target prostate cancer gene therapy by oncolytic herpes simplex virus. In: Molecular Imaging and Biology. 2006 ; Vol. 8, No. 1. pp. 30-35.
@article{067df582944048ebb9dd11b3b64d8150,
title = "Use of positron emission tomography to target prostate cancer gene therapy by oncolytic herpes simplex virus",
abstract = "Herpes simplex virus (HSV) oncolytic gene therapy is a promising treatment modality against cancer. We have demonstrated that androgen-induced cellular changes enhance oncolytic viral replication and improve efficacy in the treatment of androgen-dependent prostate cancer cell line. Imaging of changes in 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) uptake by positron emission tomography (PET) is a sensitive method of detecting altered cellular metabolism involved in cancer therapy. We therefore hypothesized that FDG-PET can predict tumor response to oncolytic HSV therapy. In this study, androgen increased cell kill (74{\%}) in vitro and enhanced viral yield (2.4-fold) in vivo following HSV therapy. This enhanced efficacy was predicted by high FDG accumulation in intact animals compared to low FDG uptake following orchiectomy (p = 0.002). This proof-of-concept study provides the mechanistic basis for selecting patients for targeted oncolytic viral therapy by means of a noninvasive molecular imaging method in the treatment of prostate cancer.",
keywords = "Fluorodeoxyglucose, Herpes virus, Hormonal therapy, Prediction",
author = "Michael Mullerad and Eisenberg, {David P.} and Akhurst, {Timothy J.} and Adusumilli, {Prasad S.} and Riedl, {Christopher C.} and Amit Bhargava and Mithat Gonen and Ronald Finn and Scardino, {Peter T.} and Yuman Fong",
year = "2006",
month = "1",
doi = "10.1007/s11307-005-0028-x",
language = "English (US)",
volume = "8",
pages = "30--35",
journal = "Molecular Imaging and Biology",
issn = "1536-1632",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Use of positron emission tomography to target prostate cancer gene therapy by oncolytic herpes simplex virus

AU - Mullerad, Michael

AU - Eisenberg, David P.

AU - Akhurst, Timothy J.

AU - Adusumilli, Prasad S.

AU - Riedl, Christopher C.

AU - Bhargava, Amit

AU - Gonen, Mithat

AU - Finn, Ronald

AU - Scardino, Peter T.

AU - Fong, Yuman

PY - 2006/1

Y1 - 2006/1

N2 - Herpes simplex virus (HSV) oncolytic gene therapy is a promising treatment modality against cancer. We have demonstrated that androgen-induced cellular changes enhance oncolytic viral replication and improve efficacy in the treatment of androgen-dependent prostate cancer cell line. Imaging of changes in 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) uptake by positron emission tomography (PET) is a sensitive method of detecting altered cellular metabolism involved in cancer therapy. We therefore hypothesized that FDG-PET can predict tumor response to oncolytic HSV therapy. In this study, androgen increased cell kill (74%) in vitro and enhanced viral yield (2.4-fold) in vivo following HSV therapy. This enhanced efficacy was predicted by high FDG accumulation in intact animals compared to low FDG uptake following orchiectomy (p = 0.002). This proof-of-concept study provides the mechanistic basis for selecting patients for targeted oncolytic viral therapy by means of a noninvasive molecular imaging method in the treatment of prostate cancer.

AB - Herpes simplex virus (HSV) oncolytic gene therapy is a promising treatment modality against cancer. We have demonstrated that androgen-induced cellular changes enhance oncolytic viral replication and improve efficacy in the treatment of androgen-dependent prostate cancer cell line. Imaging of changes in 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) uptake by positron emission tomography (PET) is a sensitive method of detecting altered cellular metabolism involved in cancer therapy. We therefore hypothesized that FDG-PET can predict tumor response to oncolytic HSV therapy. In this study, androgen increased cell kill (74%) in vitro and enhanced viral yield (2.4-fold) in vivo following HSV therapy. This enhanced efficacy was predicted by high FDG accumulation in intact animals compared to low FDG uptake following orchiectomy (p = 0.002). This proof-of-concept study provides the mechanistic basis for selecting patients for targeted oncolytic viral therapy by means of a noninvasive molecular imaging method in the treatment of prostate cancer.

KW - Fluorodeoxyglucose

KW - Herpes virus

KW - Hormonal therapy

KW - Prediction

UR - http://www.scopus.com/inward/record.url?scp=33645807822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645807822&partnerID=8YFLogxK

U2 - 10.1007/s11307-005-0028-x

DO - 10.1007/s11307-005-0028-x

M3 - Article

C2 - 16362150

AN - SCOPUS:33645807822

VL - 8

SP - 30

EP - 35

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

SN - 1536-1632

IS - 1

ER -